Chambers Review
Provided by Chambers
UK
Corporate/M&A: £100-800 million - London (Firms)
Individual Editorial
Life Sciences: Transactional - UK-wide
Individual Editorial
Andrew Edge is highly regarded for his expertise in M&A and equity capital markets advising pharmaceuticals and biotechnology companies.